Logo image of GCL

GCL GLOBAL HOLDINGS LTD (GCL) Stock Fundamental Analysis

NASDAQ:GCL - KYG3777K1031 - Common Stock

3.07 USD
-0.27 (-8.08%)
Last: 9/2/2025, 4:13:58 PM
Fundamental Rating

1

Taking everything into account, GCL scores 1 out of 10 in our fundamental rating. GCL was compared to 79 industry peers in the Entertainment industry. GCL may be in some trouble as it scores bad on both profitability and health. GCL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GCL has reported negative net income.
GCL had a negative operating cash flow in the past year.
GCL Yearly Net Income VS EBIT VS OCF VS FCFGCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500K -1M -1.5M -2M -2.5M

1.2 Ratios

The Return On Assets of GCL (-5.59%) is worse than 62.03% of its industry peers.
GCL has a Return On Equity of -9.62%. This is comparable to the rest of the industry: GCL outperforms 49.37% of its industry peers.
Industry RankSector Rank
ROA -5.59%
ROE -9.62%
ROIC N/A
ROA(3y)-2.41%
ROA(5y)N/A
ROE(3y)-3.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GCL Yearly ROA, ROE, ROICGCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GCL Yearly Profit, Operating, Gross MarginsGCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for GCL has been reduced compared to 1 year ago.
Compared to 1 year ago, GCL has a worse debt to assets ratio.
GCL Yearly Shares OutstandingGCL Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M
GCL Yearly Total Debt VS Total AssetsGCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

GCL has an Altman-Z score of 31.82. This indicates that GCL is financially healthy and has little risk of bankruptcy at the moment.
GCL has a better Altman-Z score (31.82) than 98.73% of its industry peers.
GCL has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
GCL has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: GCL outperforms 58.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 31.82
ROIC/WACCN/A
WACCN/A
GCL Yearly LT Debt VS Equity VS FCFGCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

GCL has a Current Ratio of 0.01. This is a bad value and indicates that GCL is not financially healthy enough and could expect problems in meeting its short term obligations.
GCL has a Current ratio of 0.01. This is amonst the worse of the industry: GCL underperforms 94.94% of its industry peers.
A Quick Ratio of 0.01 indicates that GCL may have some problems paying its short term obligations.
GCL has a worse Quick ratio (0.01) than 94.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
GCL Yearly Current Assets VS Current LiabilitesGCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for GCL have decreased strongly by -126.79% in the last year.
EPS 1Y (TTM)-126.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GCL Price Earnings VS Forward Price EarningsGCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GCL Per share dataGCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GCL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GCL GLOBAL HOLDINGS LTD

NASDAQ:GCL (9/2/2025, 4:13:58 PM)

3.07

-0.27 (-8.08%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)07-31 2025-07-31
Earnings (Next)02-02 2026-02-02
Inst Owners0.29%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap387.80M
AnalystsN/A
Price TargetN/A
Short Float %0.18%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 36.71
P/tB 36.71
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.59%
ROE -9.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.41%
ROA(5y)N/A
ROE(3y)-3.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z 31.82
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-126.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.74%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y66.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.7%
OCF growth 3YN/A
OCF growth 5YN/A